Custodiol与Del Nido停搏液在微创二尖瓣修复术中的倾向评分匹配研究
该单中心回顾性匹配队列研究纳入2490例微创二尖瓣手术患者,经1:1倾向评分匹配后778例接受Custodiol或Del Nido停搏液。Del Nido组术后肌酸激酶及CK-MB更低(P < .001),6小时正性肌力评分更低,围术期钠更高,开放主动脉后室性心律失常电复律更少(均P < .001);两组主要并发症相似,30天死亡率均为0%。
要点
- Del Nido停搏液在微创二尖瓣修复中显示更优的心肌保护生物标志物动态。
- Del Nido组开放主动脉后室性心律失常需电复律更少、所需电击更少。
- 两组主要并发症及30天死亡率(均0%)无差异。
核心结论
- 基于生物标志物动态和开放主动脉后室性心律失常发生率更低,Del Nido停搏液提供更优心肌保护,但总体临床结局相当。
- Del Nido停搏液可考虑作为微创二尖瓣修复术的首选单剂量停搏液。
研究设计与样本
- 排除后960例进入1:1倾向评分匹配,基于危险因素、基线特征和手术参数,最终778例匹配病例接受Custodiol或Del Nido停搏液。
- 主要结局为围术期心肌酶动态,临床结局为探索性分析。
主要发现
- Del Nido组术后肌酸激酶和CK-MB水平更低,最明显在术后前24小时(P < .001)。
- Del Nido组6小时正性肌力评分更低、围术期钠更高、开放主动脉后室性心律失常电复律更少且所需电击更少(均P < .001)。
- 两组主要并发症发生率相似,30天死亡率均为0%。
关键数值与推荐
- 术后前24小时肌酸激酶和CK-MB差异P < .001。
- 6小时正性肌力评分、围术期钠、开放主动脉后室性心律失常电复律及电击次数差异均P < .001。
- 两组30天死亡率均为0%。
临床怎么用
- 在微创二尖瓣修复术中可优先考虑Del Nido单剂量停搏液以减轻心肌损伤和减少开放主动脉后室性心律失常。
- 选择停搏液时需结合中心经验,因两组主要并发症和30天死亡率无差异。
局限性
- 单中心回顾性设计,可能存在残余混杂。
- 主要结局为心肌酶动态,临床结局为探索性分析。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Minimally invasive mitral valve repair (MIMVR) is the preferred approach to treat mitral regurgitation in specialized centres. Custodiol and Del Nido cardioplegia are widely used, yet direct comparative data on their efficacy and safety in this setting remain limited. This study investigated their efficacy and impact on early outcomes in a propensity-matched cohort. METHODS: We performed a single-centre, retrospective matched cohort study of 2490 patients undergoing minimally invasive mitral valve surgery between October 2014 and January 2025. After exclusions, 960 patients entered 1:1 propensity score matching based on risk factors, baseline characteristics and procedural parameters, yielding 778 matched cases treated with Custodiol or Del Nido cardioplegia. Perioperative dynamics of cardiac enzymes were evaluated as the primary outcome measure, along with an exploratory analysis on clinical outcomes. RESULTS: Del Nido cardioplegia was associated with lower postoperative creatine kinase and creatine kinase‑MB levels, most pronounced in the first 24 hours (P < .001). Del Nido yielded a lower inotrope score at 6 hours, higher perioperative sodium and fewer cardioversions for ventricular arrhythmia after declamping with fewer shocks required (all P < .001). Rates of major complications were similar between groups, and 30‑day mortality was 0% in both groups. CONCLUSIONS: Del Nido cardioplegia provided superior myocardial protection based on biomarker dynamics and a lower incidence of post-cross-clamp ventricular arrhythmia, while overall clinical outcomes remained comparable. It may therefore be considered the preferred single-dose cardioplegic solution for MIMVR.
引用
- Greve D, Akansel S, Holler J, et al. Custodiol Versus Del Nido Cardioplegia in Minimally Invasive Mitral Valve Repair-a Propensity Score-Matched Study. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 41782342. doi:10.1093/icvts/ivag074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。